+1-518-621-2074 | US-Canada Toll Free Contact Us

PD-1 and PD-L1 Inhibitors – A Silver Lining to Cancer Treatment

about us

Published on : Feb 28, 2017

ALBANY, NY, Feb 28, 2017: The report, titled ‘PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017’, focuses on the development of the worldwide market and its future growth prospects. The report also provides an overview of the market drivers and challenges, trends, market landscape, and key vendors. 

Cancer is the most life threatening disease and its course of treatment is long and expensive. There are many therapies and treatments in the market that are gaining prominence. Immunotherapy has become a part of the standard-of-care treatment for patients with certain cancers. The recent FDA-approved programmed death-1 (PD-1) inhibitor has proved to be a major advancement in the field and a golden chance for patients to receive a potentially beneficial therapy. PD-1 and programmed death-ligand 1 (PD-L1) inhibitors are the next targeted agents in oncology. Several of these drugs show a positive result – in terms of stability in tolerance and response – based on the data collected from initial clinical trials. 

Various factors such as rise in investment and funding, robust pipeline, and enhanced safety and efficacy are driving the market. PD-1 and PD-L1 inhibitors can be used to cure tumors including renal cancer, melanoma, and advanced or metastatic non-small cell lung cancer. These inhibitors reduce the percentage of acute toxicities and immune-mediated side effects. These are also easier to manage and result in a good response rate of any single-agent immunotherapy. All these factors have given a lot of scope to pharmaceutical industries to develop PD-L1 and PD-1 inhibitors for the treatment of different types of cancer.

Click to get more details with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=964541

The FDA approved PD-1 and PD-L1 inhibitor drugs such as Opdivo was the major revenue generator  in 2016. The global demand for Tecentriq drug is also anticipated to witness high growth that is chiefly driven by the high occurrence of urothelioma cancer and shortage of approved competitor PD-L1 inhibitors drugs. 

Although PD-1 and PD-L1 inhibitors are showing greater efficiency as immune-therapeutic drugs, it is likely that immune cells will attack other parts of the body that may cause serious problems in the liver, nerves, intestines, eyes, or other organs.

The global PD-1 and PD-L1 inhibitors market can be geographically segmented into North America, Europe, Asia Pacific, and Rest of the World. Due to technological advancements, emphasis on healthcare infrastructure, and a large pool of cancer patients, North America is the key contributor to the market growth. Asia Pacific is another attractive market for PD-1 and PD-L1 owing to an increase in disposable income, escalating aging population, and improved healthcare facilities. 

Novartis, Bristol Myer Squibb, AstraZeneca, Merck, Roche, AnaptysBio, Sorrento Therapeutics, Aurigene, Amplimmune, and BeiGene are some of the prominent players in the global PD-1 and PD-L1 inhibitors market.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]